Oncology

Access to treatment and survival outcomes among US veterans with stage I non–small cell lung cancer (NSCLC) may vary depending on demographic and sociological patterns, according to a study presented at the 2025 ASCO Annual Meeting. Read More ›

Officials with the FDA have granted traditional approval to pembrolizumab (Keytruda; Merck) with trastuzumab- (Herceptin; Genentech), fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥1. Read More ›

Cabozantinib (Cabometyx; Exelixis, Inc) has been approved by the FDA for use in patients aged >12 years who had previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET). Read More ›

On March 28, 2025, the FDA expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto; Novartis) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and who are considered appropriate to delay taxane-based chemotherapy. Read More ›

FDA officials recently approved durvalumab (Imfinzi; AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle-invasive bladder cancer. Read More ›

Officials with the FDA recently issued a communication in an attempt to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Read More ›

Initial treatment with monoclonal antibodies alone did not boost the risk for other cancers (OCs) in a group of US veterans who had been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), but initial treatment with chemoimmunotherapy was associated with a significant increase of OCs, according to results of a recently presented study. Read More ›

Addressing modifiable risk factors for anticoagulant-related bleeding in patients with cancer is an effective way to reduce bleeding and enable these patients to continue anticoagulant therapy, according to the results of a recently presented study at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›

Later cancer treatment initiation and fewer treatment options once treatment starts are just some of the impacts of longer driving distances to treatment, according to researchers reporting in a study presented at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›

In patients with newly diagnosed multiple myeloma (NDMM), the use of anti-CD38 monoclonal antibodies (mAbs) enhances the effectiveness of standard treatment protocols, according to a study presented at the 66th ASH Annual Meeting & Exposition in San Diego, CA. Read More ›